Company: SWKH
Filing Date: 2025-04-29
Form Type: ANNLRPT
Source: 0001628280-25-020720
Chunk: 101

Company: SWK Holdings Corp
Filing Date: 2025-04-29
Form: ANNLRPT
Chunk 101
---
900 |     | $          |   4,900 |     | $       | — |     | $       | — |     | $       |   4,900 |

#### Note 12.

#### Revenue Recognition
As of December 31, 2024, Enteris (Pharmaceutical Development Segment) is classified as held for sale. The Company's Pharmaceutical Development segment recognizes revenues received from contracts with its customers by revenue source, as we believe it best depicts the nature, amount, timing and uncertainty of our revenue and cash flow. The Company's Finance Receivables segment does not have any revenues received from contracts with customers.

The following table provides the contract revenue recognized by revenue source for the years ended December 31, 2024 and 2023 (in thousands):

| Pharmaceutical Development Segment   |     | December 31, 
 2024         |       |     | 2023 |       |
|:-------------------------------------|:----|:-------------|------:|:----|:-----|------:|
| License Agreement                    |     | $            |    49 |     | $    |   273 |
| Pharmaceutical development and other |     |              | 3,567 |     |      |   931 |
| Total contract revenue               |     | $            | 3,616 |     | $    | 1,204 |

The Company’s contract liabilities represent advance consideration received from customers and are recognized as revenue when the related performance obligation is satisfied.

The Company’s contract liabilities are presented as deferred income as of December 31, 2024 in the consolidated balance sheets (in thousands):

| Pharmaceutical Development Segment |     | December 31, 
 2024         |       |
|:-----------------------------------|:----|:-------------|------:|
| Balance at January 1, 2024         |     | $            |     9 |
| Income recognized                  |     |              |    -9 |
| Deferred income                    |     |              | 1,500 |
| Balance at December 31, 2024       |     | $            | 1,500 |

During the year ended December 31, 2024, the Company recognized the full remaini ng balance of $9 thousand of 2023 deferred income from satisfaction of performance obligations. The Company did not have any contra ct assets as of December 31, 2024 or December 31, 2023.

Enteris Exclusive Option and Asset Purchase Agreement